These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37691634)

  • 1. Evaluation of progression of chronic kidney disease in dogs with myxomatous mitral valve disease.
    Yun H; Koo Y; Yun T; Chae Y; Lee D; Cha S; Kim J; Kim H; Yang MP; Kang BT
    Front Vet Sci; 2023; 10():1200653. PubMed ID: 37691634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and their correlation with lipoproteins in dogs with myxomatous mitral valve disease.
    Khaki Z; Nooshirvani P; Shirani D; Masoudifard M
    BMC Vet Res; 2022 Dec; 18(1):448. PubMed ID: 36564735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of urinary neutrophil gelatinase-associated lipocalin to detect renal tubular damage in dogs with stable myxomatous mitral valve disease.
    Troia R; Sabetti MC; Crosara S; Quintavalla C; Romito G; Mazzoldi C; Fidanzio F; Cescatti M; Bertazzolo W; Giunti M; Dondi F
    J Vet Intern Med; 2022 Nov; 36(6):2053-2062. PubMed ID: 36196592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomics reveals plasma protein SERPINH1 as a potential diagnostic biomarkers for myxomatous mitral valve disease stage B2.
    Zhou Q; Wu Z; Li L; Zhou H; Chen Y; Guo S; Guo Y; Ma X; Zhang J; Feng W; Cui X; Qiu C; Xu M; Deng G
    J Proteomics; 2023 Jun; 282():104924. PubMed ID: 37146676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of serum cystatin C concentration in dogs with myxomatous mitral valve disease.
    Iwasa N; Kumazawa R; Nomura S; Shimizu M; Iwata M; Hara M; Kawabe M; Kobatake Y; Takashima S; Nishii N
    J Vet Intern Med; 2023 Mar; 37(2):412-419. PubMed ID: 36852471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Proteomic Profiles Reflect the Stages of Myxomatous Mitral Valve Disease in Dogs.
    Rešetar Maslov D; Farkaš V; Rubić I; Kuleš J; Beletić A; Beer Ljubić B; Šmit I; Mrljak V; Torti M
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut Dysbiosis and Its Associations with Gut Microbiota-Derived Metabolites in Dogs with Myxomatous Mitral Valve Disease.
    Li Q; Larouche-Lebel É; Loughran KA; Huh TP; Suchodolski JS; Oyama MA
    mSystems; 2021 Apr; 6(2):. PubMed ID: 33879495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron status in dogs with myxomatous mitral valve disease.
    Savarese A; Probo M; Locatelli C; Gazzonis AL; Zanzani SA; Traini G; Vitiello T; Brambilla PG
    Pol J Vet Sci; 2018 Sep; 21(3):507-515. PubMed ID: 30468339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of red blood cell and platelet indices in adult dogs suffered from myxomatous mitral valve disease with and without pulmonary hypertension.
    Tangmahakul N; Orton EC; Surachetpong SD
    Front Vet Sci; 2023; 10():1234768. PubMed ID: 37781288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of antioxidant status and lipid peroxidation in dogs with myxomatous mitral valve degeneration stage B1.
    Tomsič K; Domanjko Petrič A; Nemec A; Pirman T; Rezar V; Seliškar A; Vovk T; Nemec Svete A
    Front Vet Sci; 2023; 10():1203480. PubMed ID: 37745214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolomics Analysis Reveals Deranged Energy Metabolism and Amino Acid Metabolic Reprogramming in Dogs With Myxomatous Mitral Valve Disease.
    Li Q; Larouche-Lebel É; Loughran KA; Huh TP; Suchodolski JS; Oyama MA
    J Am Heart Assoc; 2021 May; 10(9):e018923. PubMed ID: 33890477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of sampling time on urinary electrolytes following oral furosemide administration in dogs with myxomatous mitral valve disease.
    Sabetti MC; Fidanzio F; Troìa R; Perissinotto L; Romito G; Mazzoldi C; Quintavalla C; Crosara S; Dondi F
    J Vet Cardiol; 2022 Jun; 41():57-69. PubMed ID: 35245876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dietary intervention reduces left atrial enlargement in dogs with early preclinical myxomatous mitral valve disease: a blinded randomized controlled study in 36 dogs.
    Li Q; Heaney A; Langenfeld-McCoy N; Boler BV; Laflamme DP
    BMC Vet Res; 2019 Nov; 15(1):425. PubMed ID: 31775756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symmetric dimethylarginine in dogs with myxomatous mitral valve disease at various stages of disease severity.
    Valente C; Guglielmini C; Domenech O; Contiero B; Zini E; Poser H
    PLoS One; 2020; 15(9):e0238440. PubMed ID: 32870923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Left atrial deformation and phasic function determined by two-dimensional speckle-tracking echocardiography in dogs with myxomatous mitral valve disease.
    Caivano D; Rishniw M; Birettoni F; Patata V; Giorgi ME; Porciello F
    J Vet Cardiol; 2018 Apr; 20(2):102-114. PubMed ID: 29459124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence of pulmonary hypertension in Cavalier King Charles spaniels compared with other breeds with myxomatous mitral valve disease.
    Sudunagunta S; Green D; Christley R; Dukes-McEwan J
    J Vet Cardiol; 2019 Jun; 23():21-31. PubMed ID: 31174726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of serum ionized magnesium concentration in dogs with myxomatous mitral valve disease.
    Kim OK; Kim K; Park S; Yang H; Kim H; Ro WB; Lee CM
    J Vet Intern Med; 2024; 38(1):41-50. PubMed ID: 38064361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of concurrent lower respiratory tract disease on point-of-care lung ultrasound in small-breed dogs with myxomatous mitral valve disease.
    Lam MC; Lin CH; Lo PY; Wu HD
    J Vet Intern Med; 2022 May; 36(3):1075-1081. PubMed ID: 35475522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of pulmonary vascular resistance estimated by echocardiography in dogs with myxomatous mitral valve disease and pulmonary hypertension.
    Yuchi Y; Suzuki R; Yasumura Y; Saito T; Teshima T; Matsumoto H; Koyama H
    J Vet Intern Med; 2023; 37(3):856-865. PubMed ID: 36994902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can cartilage intermediate layer protein 1 (CILP1) use as a novel biomarker for canine myxomatous mitral valve degeneration levels or not?
    Kim HJ; Kim J; Kim S; Kim HJ
    BMC Vet Res; 2023 Mar; 19(1):59. PubMed ID: 36882760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.